Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 397 participants.

Also called NCT02305381

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 397 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02305381
  • EudraCT 2013-004502-26
Main results
  • Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial The Journal of clinical endocrinology and metabolism, 2018-06-01 DOI, PubMed 29688502, PMC5991220 In the PMC Open Access subset under CC BY.
Other papers using this trial's data
  • Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29687620, PMC6099273 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766634, PMC6099440 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Japan, Puerto Rico, Serbia, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02305381. Randomized; double masking; primary purpose treatment. Start 2014-12-01 (actual); primary completion 2015-11-21 (actual). Results posted on 2018-02-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
Acronym
SUSTAIN™ 5
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02305381
Content hash
5a0d72ab8bbda50fa073130afaf874f8610d82b63993bf91a65f82de724b2ff5